Strategy & Management

Today’s Challenges, Tomorrow’s Excellence

How the pharmaceutical ingredients & custom synthesis industry attunes to rapidly shifting demands

01.10.2014 -

Pharmaceutical companies have outsourced several critical steps in the discovery and development of new drugs and the scale-up of processes and the manufacturing of APIs. Pharma, therefore, depends and relies on numerous service and technology partners. Prior to this year's CPhI Worldwide CHEManager International asked experts from CROs, CMOs, manufacturers of APIs, excipients and catalysts, formulators and others to describe their changing role in the pharmaceutical value chain. Read their answers to our questions.

1. What roles do contract research organizations (CROs) and contract manufacturing organizations (CMOs) play in the drug discovery/development value chain today, and how will their role change in the future?

2. How have the requirements by pharma companies changed over the years, and how can suppliers manage to live up to them?

3. Which new business models, like project-based or value-based outsourcing, could turn out to be the most promising guarantors for a successful cooperation with the pharmaceutical industry?

4. The establishment of shared risk/shared reward partnerships has increased significantly. Can these partnerships accelerate drug discovery and fill up the innovation pipelines?

Kurt Hoeprich
Business Manager, Custom Services, Albemarle


Elliott Berger
VP Global Marketing & Strategy, Catalent


Dr. Michael Stohlmeier
Senior Product Manager - Business Development, CU Chemie Uetikon



Dr. Markus Blocher
CEO, Dottikon



Christian Jones
Associate Director - Business Development, Dr. Reddy's


Andreas Weiler
Global Head of Strategic Marketing, SAFC


Dr. Max Braun
Senior R&D and Business Development Manager, Solvay


Dr. Wilfried Eul
Head Business Line Catalysts, Evonik

Christophe Le Ret
Director of Strategic Marketing, Precious Metals Chemistry, Umicore

Nicolas Taillardat
Global Marketing and Sales Manager, Organic Intermediates and Solkane Pharma, Solvay

Dr. Andrea Missio
Business Development Director, WeylChem

John Nicols
President and CEO, Codexis


Dr. Jean-Luc Herbeaux
Head Business Line Health Care, Evonik


Jan Bebber
Global Platform Marketing Manager, Pharma Ingredients, BASF


Dr. Lukas Utiger
President and CEO, DSM Pharmaceutical Products


Jörg Schneider
Head of Marketing, Saltigo


Dr. Rudolf Hanko
CEO, Siegfried

Dr. Gabriel Haering
CEO, Cerbios

Ian Muir
Managing Director, Finished Dose, Aesica